Bogle Grant C. — SEC insider filings
SEC reporting owner CIK 1646675. 12 insider filings on record with FilingPulse; latest filed 2026-11-09.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2021-06-15 to 2026-11-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 25.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Epizyme, Inc. (EPZM) | President and CEO, Director | 6 | — | — | 15 |
| Nuvalent, Inc. (NUVL) | Director | 4 | — | — | 9 |
| Immuneering Corp (IMRX) | Director | 2 | — | — | 1 |
Insider filings — Bogle Grant C.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-09 | 3 | Immuneering Corp (IMRX) | Holdings only — no transactions reported | EDGAR |
| 2026-11-09 | 4 | Immuneering Corp (IMRX) | Grant/award (A): 66,700 (derivative) @ $0 | EDGAR |
| 2026-07-15 | 4 | Nuvalent, Inc. (NUVL) | Code (U): 3,714 @ $124 · Disposition to issuer (D): 5,577 · Disposition to issuer (D): 4,851 (derivative) · Disposition to issuer (D): 4,147 (derivative) | EDGAR |
| 2026-06-18 | 4 | Nuvalent, Inc. (NUVL) | Grant/award (A): 3,444 @ $0 | EDGAR |
| 2025-06-20 | 4 | Nuvalent, Inc. (NUVL) | Grant/award (A): 2,647 @ $0 · Grant/award (A): 4,147 (derivative) @ $0 | EDGAR |
| 2024-12-09 | 4 | Nuvalent, Inc. (NUVL) | Grant/award (A): 3,200 @ $0 · Grant/award (A): 4,851 (derivative) @ $0 | EDGAR |
| 2022-08-16 | 4 | Epizyme, Inc. (EPZM) | Disposition to issuer (D): 84,170 · Disposition to issuer (D): 175,000 | EDGAR |
| 2022-08-11 | 4 | Epizyme, Inc. (EPZM) | Option exercise (M): 800,000 @ $1.39 · Tax withholding (F): 746,307 @ $1.39 · Option exercise (M): 417,500 @ $1.41 · Tax withholding (F): 395,083 @ $1.41 · Option exercise (M): 800,000 (derivative) @ $0 · Option exercise (M): 417,500 (derivative) @ $0 | EDGAR |
| 2022-03-21 | 4 | Epizyme, Inc. (EPZM) | Grant/award (A): 800,000 (derivative) @ $0 | EDGAR |
| 2022-02-04 | 4 | Epizyme, Inc. (EPZM) | Grant/award (A): 87,500 @ $0 · Grant/award (A): 417,500 (derivative) @ $0 | EDGAR |
| 2021-08-18 | 4 | Epizyme, Inc. (EPZM) | Grant/award (A): 87,500 @ $0 · Grant/award (A): 417,500 (derivative) @ $0 | EDGAR |
| 2021-06-15 | 4 | Epizyme, Inc. (EPZM) | Grant/award (A): 8,060 @ $0 · Grant/award (A): 40,559 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-02-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1646675 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs